Since 1975, Statement of Financial Accounting Standards No. 2 (SFAS#2) has required U.S. corporations to expense most research and development (R&D) costs in the period incurred, primarily because of the uncertain nature of future benefits derived from R&D (SFAS#2 [1974b, para. 39-49, 52]). However, SFAS#2 may have had some unintended economic consequences. (1) For small, research-intensive firms, required expensing of R&D costs generally would result in lower and/or more volatile reported earnings, lower stockholders' equity, and a higher debt-to-equity ratio. These could translate into higher capital costs and subsequently lower capital investment in these firms. The public record of position papers and testimony before the FASB [1974a] shows that smaller, developing firms (and several large public accounting firms) were strongly opposed to mandatory expensing of R&D. (2) If managers are evaluated on reported earnings, required expensing of R&D costs could bias managers against investments in R&D (e.g., in favor of other capitalizable investments) (AAA [1977] and Selto [1982]). For example,
Read full abstract